Thanacoody Ruben H K
National Poisons Information Service (Newcastle Unit), Regional Drugs and Therapeutics Centre, School of Clinical and Laboratory Sciences, University of Newcastle, Newcastle upon Tyne, UK.
Clin Toxicol (Phila). 2009 Aug;47(7):609-16. doi: 10.1080/15563650903167772.
Valproic acid (VPA) is an antiepileptic drug that is now used for a variety of neurological and psychiatric indications. Clinical manifestations of severe VPA poisoning include central nervous system depression, hypotension, electrolyte and acid-base disturbances, and hyperammonemia. Although extracorporeal methods have been used to enhance VPA elimination, the indications for and effectiveness of these methods have not been fully characterized.
A systematic literature search was performed, which identified 31 reports of the use of extracorporeal elimination in VPA poisoning.
VPA has a low molecular weight of 144 Da and a low volume of distribution, but at therapeutic concentrations, it is highly protein bound (85-95%). Protein-binding studies during hemodialysis demonstrate that at high VPA concentrations protein binding is saturated, allowing substantial clearance of the free VPA fraction. Case reports consistently show that during hemodialysis the elimination half-life of VPA can be reduced to around 2 h and the enhanced VPA clearance is often associated with improvement clinically. Hemoperfusion also enhances VPA elimination, but its effectiveness may be limited by column saturation. "In-series" hemodialysis and hemoperfusion have been used, but the combination offers little benefit over hemodialysis alone. Continuous renal replacement techniques are increasingly being used although continuous venovenous hemofiltration and continuous venovenous hemodiafiltration do not appear to be as effective as hemodialysis. No controlled trials are available comparing clinical outcomes with or without extracorporeal elimination in VPA poisoning. Novel techniques such as slow low-efficiency dialysis with filtration and supplementation of the dialysate with albumin are being evaluated.
Extracorporeal methods of elimination should be considered in patients with features of severe VPA poisoning (coma or hemodynamic compromise) and plasma VPA concentration >850 mg/L (coma is more likely to be present at concentrations >850 mg/L), particularly if severe hyperammonemia and electrolyte and acid-base disturbances are present.
Based on limited anecdotal evidence, hemodialysis appears to be the extracorporeal method of choice to enhance VPA elimination in acute poisoning. Controlled, randomized trials are required to better characterize the effect of extracorporeal treatment on clinical outcome.
丙戊酸(VPA)是一种抗癫痫药物,目前用于多种神经和精神疾病的治疗。严重VPA中毒的临床表现包括中枢神经系统抑制、低血压、电解质和酸碱平衡紊乱以及高氨血症。尽管已经采用体外方法来促进VPA的清除,但这些方法的适应证和有效性尚未完全明确。
进行了系统的文献检索,共识别出31篇关于在VPA中毒中使用体外清除方法的报告。
VPA的分子量低,为144道尔顿,分布容积小,但在治疗浓度下,它与蛋白质的结合率很高(85%-95%)。血液透析期间的蛋白质结合研究表明,在高VPA浓度下,蛋白质结合会饱和,从而使游离VPA部分得以大量清除。病例报告一致显示,在血液透析期间,VPA的消除半衰期可缩短至约2小时,VPA清除率的提高通常与临床症状改善相关。血液灌流也能促进VPA的清除,但其有效性可能会受到柱饱和的限制。已经使用了“串联”血液透析和血液灌流,但这种联合方法与单独进行血液透析相比,益处不大。连续肾脏替代技术的应用越来越多,尽管连续静脉-静脉血液滤过和连续静脉-静脉血液透析滤过似乎不如血液透析有效。目前尚无对照试验比较VPA中毒患者接受或未接受体外清除治疗的临床结局。正在评估诸如缓慢低效透析滤过以及在透析液中补充白蛋白等新技术。
对于具有严重VPA中毒特征(昏迷或血流动力学不稳定)且血浆VPA浓度>850mg/L(浓度>850mg/L时更可能出现昏迷)的患者,尤其是存在严重高氨血症以及电解质和酸碱平衡紊乱的患者,应考虑采用体外清除方法。
基于有限的轶事性证据,血液透析似乎是急性中毒时促进VPA清除的首选体外方法。需要进行对照、随机试验,以更好地明确体外治疗对临床结局的影响。